Gambro and Nephrogen enter into new Partnership
Gambro AB has signed an agreement with German-based Nephrogen, LLC as part of its Regenerative Medicine initiative announced earlier this year. The program will extend over a period of three years with the target to restore the function of the kidney using adult stem cells. Initial research will focus on the indication of acute renal failure.
Gambro has earlier announced that it would invest around USD 12,6 million over three years in the field of regenerative medicine. The funds will be used for internal research as well as to support outside collaborators such as Nephrogen. The next three years funds will finance cell selection and expansion technology and clinical trials. Gambro will primarily focus on developing new tools for cell handling and processing, while Nephrogen will contribute with scientific and clinical expertise. The objective with the current program is to publish first clinical results in two to three years.
Regenerative medicine involves the use of adult stem cells for improving and restoring the functionality of organs. While therapeutic use of adult stem cells is currently an area of intense research, it is a largely unproven field with uncertain outcomes. Success, however holds the promise of making a very significant contribution in the advancement of care for large numbers of patients suffering from renal and other diseases. Gambro BCT currently provides products that are used for the collection and processing of adult stem cells and it is anticipated that this effort will result in broadening this offering as well as possibly leading to other fields of commercial endeavor.
Gambro AB is a global medical technology company with related services and has leading positions in renal care - services and products - and blood component technology. Gambro Renal Products develops and supplies hemodialysis, peritoneal dialysis, and acute renal and liver dialysis products, therapies and services. Gambro Healthcare is a provider of end-stage renal disease treatment and patient care. Gambro BCT develops and provides blood collection, aphaeresis and cell therapy products and services.
For further information please contact:
Paula Treutiger,
Vice President, Corporate Communications
Tel: +46 8 613 65 99
Email: paula.treutiger@gambro.com
Or visit: www.gambro.com